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Abstract
In studies describing the long-term follow-up up of youth at clinical high risk (CHR) of psychosis, 
little attention has been given to details of specific prodromal symptoms. In this paper we describe 
the prodromal symptoms of 764 CHR participants recruited in the multi-site North American 
Prodrome Longitudinal Study (NAPLS). Symptoms were rated on the Scale of Prodromal 
Symptoms (SOPS) at baseline and 6, 12, 18 and 24 month follow-ups. Clinical outcome at the 2-
year assessment was categorized as psychotic, prodromal progression, symptomatic or in 
remission. The majority of the CHR sample (93%) met criteria for the attenuated positive 
symptoms syndrome (APSS). Significant improvements in SOPS symptoms were observed 
overtime. Unusual thought content, disorganized communication and overall ratings on 
disorganized symptoms differentiated those who transitioned to psychosis from the other clinical 
outcome groups. Suspiciousness and total positive symptoms differentiated those in remission 
from the other clinical outcome groups.
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INTRODUCTION
Interest in early detection and prevention of schizophrenia and other psychotic disorders has 
led to more than a decade of work studying young people who may be at risk of developing 
a psychotic illness. Several reviews and meta analyses have been published focusing on the 
development of the field (Fusar-Poli et al., 2012b), clinical studies (Addington and 
Heinssen, 2011), treatment outcome (Stafford et al., 2013) and conversion to psychosis 
(Fusar-Poli et al., 2012a). Identifying predictors and mechanisms of conversion to psychosis 
among such individuals ascertained to be in a clinical high risk (CHR) or prodromal clinical 
state are critical steps in the search for preventive strategies for psychosis. Achieving these 
aims requires sample sizes much larger than those typically available at a single research 
centre within a reasonable time period. The majority of the studies described in the reviews 
above were single site studies with small samples. However, three notably large samples 
have been described in the literature, namely the Personal Assessment and Crisis Evaluation 
(PACE) clinic in Melbourne Australia, the European Prediction of Psychosis Study (EPOS) 
and the North American Prodrome Longitudinal Study (NAPLS).
The work from the PACE clinic (Nelson et al., 2013) describes the long term follow-up of 
416 young people at CHR of psychosis that have been treated at the PACE clinic and/or 
participated in one of their studies between 1993 and 2006. EPOS is a prediction study of 
245 individuals meeting criteria for being at CHR of psychosis who were recruited from six 
early detection outpatient centers in Germany, Finland, the Netherlands and England 
(Ruhrmann et al., 2010). NAPLS is a consortium of eight programs focusing on the 
psychosis prodrome in North America. The sites are located at Emory University, Harvard 
University, University of Calgary in Canada, University of California at Los Angeles, 
University of California at San Diego, University of North Carolina at Chapel Hill, Yale 
University, and Zucker Hillside Hospital. In the first phase of the NAPLS project (NAPLS 
1), these sites collaborated to combine previously collected datasets and produced a series of 
analyses on predictors of psychosis in a sample of 291 CHR participants followed 
longitudinally (Addington et al., 2007). Results of these analyses indicated that risk for the 
onset of psychosis in this population was 35% after 2 ½ years of follow-up, with a 
decelerating rate of conversion over this period. The NAPLS 1 data set was used to derive a 
psychosis prediction algorithm with high positive predictive power (~80%), but only modest 
sensitivity (~40%) (Cannon et al., 2008). The published prediction algorithm included 
genetic risk (having a first degree relative with a psychotic disorder and functional decline), 
more severe unusual thought content, and greater social impairment.
This first project from the NAPLS group resulted in a six year prospective study “Predictors 
and Mechanisms of Conversion to Psychosis”, funded by NIMH in 2008, and described as 
NAPLS 2 that included all eight NAPLS sites. The sample size of NAPLS 2 is anticipated to 
be sufficient to address fundamental questions about the neurobiological correlates of the 
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development of psychosis. The project has recruited a sample of 764 CHR participants and 
280 healthy controls, making it the largest study of individuals at CHR of psychosis to date. 
The overall methodology of NAPLS 2 and a description of the ascertainment and 
demographics has been described in detail elsewhere (Addington et al., 2012). Assessment 
areas for NAPLS 2 include psychopathology, early risk factors, social functioning, social 
cognition, neuropsychology, treatment monitoring, neuroimaging, electrophysiology, stress 
and hormones and genomics (Addington et al., 2012). Interestingly, despite the fact that 
individuals at CHR of psychosis are identified on the basis of clinical symptoms, i.e. the five 
attenuated positive symptoms from the Scale of Prodromal Symptoms (SOPS), little has 
been published about these prodromal symptoms, particularly individual symptoms. Thus, 
the focus of this paper will be on the prodromal symptoms.
Several studies have reported on the severity of attenuated psychotic symptoms. The EPOS 
study (Ruhrmann et al., 2010) reported that at baseline, the SOPS negative symptoms were 
rated with the greatest severity, followed by SOPS positive, general and disorganization 
symptoms, a finding supported elsewhere (Comparelli et al., 2014;Fulford et al., 2014;Lee et 
al., 2014;Velthorst et al., 2009). Findings from NAPLS 1 (Piskulic et al., 2012) indicated 
that for 138 participants at CHR of psychosis, 82% presented with moderate severity (i.e. 
score of 4 on the SOPS) or greater on at least one negative symptom. Moreover, after 12 
months, these symptoms remained in the above moderate severity range for 54% of the 
sample. Another study from NAPLS 1 (Alderman et al., 2014) reported that amongst Latino 
CHR participants, positive symptoms were rated with the highest severity and that unusual 
thought content was particularly prevalent. Amongst negative symptoms, social anhedonia 
was the most common. Trouble with focus and attention was the most common disorganized 
symptom while dysphoric mood was the most common general symptom.
In terms of change over time, a Japanese study (Morita et al., 2014) reported similar severity 
of positive and negative symptoms at baseline in a CHR sample but that after one year, 48% 
of the sample showed little improvement in either positive or negative symptoms. In 
contrast, findings from NAPLS 1 suggest that those at CHR of psychosis who did not 
transition to psychosis over a 2.5 year period showed significant improvement in SOPS 
positive and negative symptoms between baseline and one year later (Addington et al., 
2011). Lee and colleagues (Lee et al., 2014) reported that CHR participants who achieved 
remission of positive symptoms at two years had lower SOPS positive symptom scores at 
baseline, compared to CHR non-remitted individuals, and that SOPS positive symptom 
score was a significant predictor of longer time to remission. Examination of the severity of 
specific attenuated psychotic symptoms is rare. One study (Simon et al., 2009) reported that 
full remission of SOPS subclinical hallucinations occurred in 54% of CHR participants and 
either full or partial remission occurred in 68% of these individuals after one year in the 
study.
There are even less data on the frequency of individual SOPS symptoms as well as the 
timing of the onset of these attenuated psychotic symptoms in CHR individuals. A 
retrospective study in patients with a first-episode of psychosis reported that attenuated 
psychotic symptoms occurred on average 3.9 years before admission to a hospital for a 
psychotic episode (Schultze-Lutter et al., 2010). A recent prospective study (Woodberry et 
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al., 2014) reported that in a sample of 39 people at CHR for psychosis, for 23% the onset of 
SOPS unusual thought content, suspiciousness or perceptual abnormalities occurred in 
childhood, for 38.5% in adolescence, and for 38.5% in adulthood.
The aim of this paper is to (i) describe the extent of prodromal symptoms in the large 
NAPLS2 study, (ii) examine the change over time of these symptoms and (iii) determine the 
role of these early symptoms in terms of later clinical follow-up.
METHODS
Participants
NAPLS participants were help-seeking and were referred from health care providers, 
educators, or social service agencies, or they self-referred in response to intensive 
community education efforts. These initiatives included grand rounds, educational talks, 
mailings, postings, websites and internet hits, and public service announcements. Each of 
the eight sites developed extensive referral sources in their area, and routinely contacts them 
personally, with mail outs, and through educational efforts. Potential participants underwent 
a telephone screen. Those who screened positive were invited to an in-person eligibility and 
consent evaluation.
The CHR sample met the Criteria of Prodromal Syndromes (COPS) which is based on the 
Structured Interview for Prodromal Syndromes (SIPS)(McGlashan et al., 2010). The COPS 
has three possible prodromal syndromes - attenuated positive symptom syndrome (APSS), 
genetic risk and deterioration (GRD) and/or brief intermittent psychotic syndrome (BIPS). 
APSS requires the presence of at least one attenuated positive psychotic symptom (unusual 
thought content, suspiciousness, grandiose ideas, perceptual abnormalities, or disorganized 
communication) of insufficient severity to meet diagnostic criteria for a psychotic disorder. 
The attenuated psychotic symptom(s) has to have begun or worsened in the past year. The 
GRD requires having a combination of both functional decline (at least a 30% drop in 
Global Assessment of Function score over the last month as compared to 12 months ago) 
and genetic risk; genetic risk refers to having either schizotypal personality disorder or a 
first-degree relative with a schizophrenia spectrum disorder. The BIPS state requires the 
presence of any one or more threshold positive psychotic symptoms (unusual thought 
content, suspiciousness, grandiosity, perceptual abnormalities, and disorganized 
communication) that are too brief to meet diagnostic criteria for psychosis. The APSS 
criteria used in NAPLS 2 is similar to the more recent addition to DSM-V the Attenuated 
Psychosis Syndrome (APS) which is characterized by psychotic-like symptoms that are 
below threshold for full psychosis (Tsuang et al., 2013). Criteria are similar except that APS 
requires that they are sufficiently distressing and disabling to the individual to lead them to 
seek help. However, the very nature of recruitment for NAPLS 2 means the participants are 
help-seeking.
After a comprehensive assessment that included administering the Structured Clinical 
Interview for DSM-IV (SCID) (First et al., 1995) and the SIPS, vignettes were developed for 
each CHR participant for the purpose of obtaining a consensus diagnosis. The attenuated 
psychotic symptoms rated on the Scale of Prodromal Symptoms (SOPS) are described at 
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length and include both recent and longstanding symptoms. The vignettes are written so that 
raters from all other sites can review the information under each symptom category and 
provide a reliable rating. Once approved at the site level, the vignette is presented on a 
conference call for a consensus decision on the symptom ratings as well as the diagnosis. 
The NAPLS-2 consensus call, chaired by JA, was held once a week and was attended by 
members of each of the eight sites. Submitted vignettes are individually reviewed and a 
consensus must be reached on each symptom rating, diagnosis and ultimate admission into 
the study. It was often challenging making differentiations with respect to some of the 
exclusion criteria listed below, but the calls were used to discuss issues such as the impact of 
substance abuse and use of antipsychotics.
Cross-site reliability in the ratings of the SOPS was conducted on an annual basis using a 
new videotape each year. Ratings from all raters at all sites were compared to “gold 
standard” ratings on the SOPS. Intraclass correlations, over four years, for the total SOPS 
scores ranged from 0.82 to 0.93 and for the attenuated positive symptom score from the 
SOPS ranged from 0.92 to 0.96. There were minimal differences across the individual sites. 
All intraclass correlations were in the excellent range.
Inclusion and exclusion criteria
Individuals at CHR had to be between 12 and 35 years old and meet diagnostic criteria for a 
prodromal syndrome as per the COPS criteria (McGlashan et al., 2010), or if under 19, meet 
criteria for schizotypal personality disorder (SPD). Participants were excluded if they met 
criteria for current or lifetime Axis I psychotic disorder, including affective psychoses, IQ < 
70, or had a past history of a central nervous system disorder, substance dependence in the 
past 6 months, or if the diagnostic prodromal symptoms were clearly caused by an Axis I 
disorder. Other non-psychotic DSM-IV disorders were not exclusionary (e.g., substance 
abuse disorder, major depression, anxiety disorders, Axis II disorders), as long as the 
disorder did not account for the individual's prodromal symptoms. Use of antipsychotics was 
not an exclusion provided there was clear evidence that prodromal (but not psychotic) 
symptoms were present when the medication was started. Control subjects could not meet 
criteria for any prodromal syndrome, any current or past psychotic disorder or a Cluster A 
personality disorder diagnosis, and could not have a family history (in first-degree relatives) 
of any psychotic disorder or any other disorder involving psychotic symptoms. They could 
not be currently using psychotropic medication.
Measures
The SCID (First et al., 1998) was used to rule out the presence of psychosis. The SIPS and 
the SOPS were used to assess COPS criteria and severity of attenuated positive symptoms 
and negative symptoms.
The SOPS is a 19-item scale designed to measure the severity of prodromal symptoms. The 
SOPS contains four subscales for Positive, Negative, Disorganization and General 
Symptoms. The five positive symptoms are P1-unusual thought content/delusional ideas, 
P2-suspiciousness/persecutory ideas, P3-grandiose ideas, P4-perceptual abnormalities, P5-
disorganized communication. The six negative symptoms are N1-social anhedonia, N2-
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avolition, N3-expression of emotion, N4-experience of emotion and self, N5-ideational 
richness, N6-occupational functioning. The four disorganization symptoms are D1-odd 
behavior or appearance, D2-bizarre thinking, D3- trouble with focus and attention, D4-
impairment in personal hygiene. The four general symptoms are G1-sleep disturbance, G2-
dysphoric mood, G3-motor disturbances, G4-impaired tolerance to normal stress. Positive 
symptoms are rated from 0 (absent) to 6 (severe/psychotic). Negative, disorganized and 
general symptoms are rated from 0 (absent) to 6 (extreme).
Clinical outcome at each follow-up assessment was determined in the following way: (i) 
remission (remission from all syndromes which means scores of 2 or less on all five positive 
symptoms on the SOPS scale, or for those who have only GRD, “in remission” will require 
GAF to have returned to 90% of previous best GAF.); (ii) symptomatic (not currently 
meeting criteria for a prodromal risk syndrome but having ratings of 3-5 on any one of the 
five positive symptoms on the SOPS, or with the no change in the GAF); (iii) prodromal 
progression (currently meeting criteria for one of the at risk syndromes; APSS, GRD, BIPS) 
and (iv) psychotic (currently meeting criteria for a psychotic disorder or evidencing scores 
of 6 on one or more positive symptoms of the SOPS).
Transition to psychosis was determined by meeting the Presence of Psychotic Symptoms 
(POPS) (Miller et al, 2003) criteria. Transition criteria is that at least one of the five SOPS 
positive symptoms reached a psychotic level of intensity (rated 6) for a frequency of ≥ 1 
hour per day for 4 days per week during the past month or that symptoms seriously impacted 
functioning (e.g., severely disorganised or dangerous to self or others).
Statistical Analysis
Chi-square and t-tests were used to compare groups on demographics. One-way ANOVAs 
were used to compare the different clinical outcome groups on prodromal symptoms. To 
accommodate missing data and account for intra-participant correlation over time, the 
generalized linear mixed model for repeated measures was used for the whole CHR sample 
to examine changes over time (baseline, 6 months, 12 months, 18 months and 24 months) 
for the five positive symptoms, the six negative symptoms and the total sub-scores for 
positive, negative, disorganized and general symptoms on the SOPS for those at CHR.
RESULTS
Sample Characteristics
The sample consisted of 280 individuals in the control group (141 males and 139 females) 
and 764 in the CHR group (436 males and 328 females). The controls (HC) were 
significantly older than the CHR group (19.7 versus 18.5 years), and had significantly more 
years of education (12.7 years versus 11.3 years). The groups did not differ in ethnicity, with 
the majority being white (CHR 62.6%, HC 59.6%) or marital status with the majority being 
single (95%) or living at home (CHR 75.9%, HC 63.2%) or enrolled as a student (CHR 
82.3%, HC 81.1%). Significantly more of the controls were working (46.1% vs 25%). These 
details are presented in Table 1. In addition the majority of all participants were born in the 
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USA or Canada. Eighty percent of CHR and 93% of control participants had English as their 
first language. Spanish was the first language of 50% of the non-English speaking group.
Of the total CHR sample, 93 (12.2%) transitioned to a psychotic disorder, 151 (19.8%) did 
not have any follow-up, 87 (11.4%) had only the 6-month follow-up, 103 (13.4%) were only 
followed to 12 months, 56 (7.3%) to 18 months and 274 (36.9%) completed a two year 
follow-up. Ninety-three of 764 cases converted to psychosis, with a mean ± SD time to 
conversion of 288.3 ± 287.1 days since the baseline evaluation. However eight of the cases 
converted after the final 24 month follow-up.
Clinical presentation
The majority of the CHR sample (92.0%) met criteria for the attenuated positive symptoms 
syndrome, either alone (83.9%) or in combination. A small proportion met other criteria. 
This information is presented in Table 2.
The mean age at the presentation of the first attenuated psychotic symptom was 16.3 years, 
(SD=4.60, median =15.5 years). These data were available for 674 CHR participants in the 
sample. The mean length of time since the appearance of the first positive symptom was 
792.7 days (SD = 950.5, median=365.5 days, range=16 days to 19 years).
The means and standard deviations of all 19 SOPS symptoms are presented in Table 3. The 
most common positive symptoms were unusual thought content and perceptual 
abnormalities. For negative symptoms this ranged from 56.4% endorsing poor functioning to 
19.4% endorsing decreased ideational richness. Apart from “trouble with focus and 
attention” disorganization symptoms were infrequently endorsed. With the exception of 
impaired tolerance to normal stress, approximately 50% endorsed each of the general 
symptoms. See Table 3.
Change in symptoms over time
Results of the mixed-effect models demonstrated that overall, there were significant 
improvements in all 19 SOPS symptoms at each follow-up time point compared with 
baseline. Although most of the clinical improvement occurred in the first 6 months, there 
was still significant continued improvement occurring between 6 and 12 months for P1, P4, 
positive total, N1, negative total and D2 symptoms and between 12 and 18 months for P1, 
P2, P4, P5, positive total, N4, N5, D2, D3 symptoms. There were continued improvements 
from 12 to 18 or 12 to 24 months for all positive symptoms except P3, N1, N3, N5, N6, D2 
and D3. However, there were no significant improvements in any SOPS symptoms between 
18 and 24 months.
Clinical Outcome
Since 52% of the sample was not available at the 2-year outcome, we examined clinical 
outcome in two ways. First, for the 48% that either completed two years or converted and 
secondly as a last observation carried forward (LOCF). These numbers are presented in 
Table 4.
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For the group that reached two years, the smallest subgroup comprised those who continued 
to meet prodromal progression. For the group using the LOCF, the subgroups were quite 
even with the psychotic subgroup being the smallest.
Using the LOCF, the clinical outcome groups varied on the following baseline symptoms: 
P1-unusual thought content (F=8.89, p<0.001), P2-suspiciousness (F=11.67, p<0.001), P5-
disorganization (F=6.31, p<0.001), N2-avolition (F=2.85, p<0.05), positive symptom total 
score (F=12.77, p<0.001), and disorganization total score (F=6.96, p<0.001). There were no 
differences for P3 (grandiosity) , P4 (perceptual abnormalities), or any of the negative 
symptoms with the exception of N2 (anhedonia). When restricting the analyses to include 
only the subgroup with clinical outcome data at two years, ANOVA results demonstrated 
that with the exception of N2, the groups differed on the same baseline symptoms: P1 
(F=9.97, p<0.001), P2 (F=6.47, p<0.001), P5 (F=5.57, p<0.01), positive total (F=9.38, 
p<0.001), and disorganization total (F=5.40, p<0.01). However, post hoc examinations 
revealed that the intergroup differences were not always the same. These are presented in 
Table 5.
DISCUSSION
The current study presents symptom data on the largest sample of adolescents and adults at 
CHR of psychosis to date. In terms of demographics, CHR subjects vary little from healthy 
controls, being on average younger by one year, which may account for the one year 
difference in years of education, and more likely to be living at home.
More than 92% of the CHR sample met criteria for attenuated psychotic symptom syndrome 
(APSS). Although 10% did present with genetic risk and deterioration (GRD), less than 5% 
met only this criterion, as those who met for GRD typically also present with APSS. 
Furthermore, the Brief Intermittent Psychotic symptom criterion (BIPS) rarely occurred on 
its own (n=6 cases, 0.8%). More frequently, we saw individuals who presented with APSS 
but reported an occurrence of BIPS in the past three months, although that too was 
infrequent (n=14 cases, 1.9%).
Next, we examined all prodromal symptoms individually. Our data support the few previous 
studies that suggest that the most common symptoms at baseline are positive in that 92% 
have at least one positive symptom, followed by negative and then disorganization and 
general. Eighty-two percent of the sample had at least one negative symptom and 44% had 
three or more negative symptoms. The most frequently endorsed positive symptoms were 
unusual thought content and perceptual abnormalities, followed by suspiciousness. 
Disorganized communication was infrequent and grandiosity endorsed even less often. 
Avolition and poor occupational functioning were the most common negative symptoms. 
None of the other symptoms were endorsed as much as unusual thought content and 
perceptual abnormalities, although dysphoric mood was endorsed by 68% of the sample.
Two earlier studies have reported symptom improvement over time (Lee et al., 
2014;Addington et al., 2011). We observed that there were significant improvements in all 
19 SOPS symptoms at each follow-up time point compared to baseline. Although most of 
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the clinical improvement occurred in the first six months, there was still significant 
continued improvement occurring between 6 and 12 months for unusual thought content, 
perceptual abnormalities, anhedonia, bizarre thinking, and overall positive symptoms and 
negative symptoms. Several symptoms continued to improve between 12 and 18 months, 
although none improved between 18 and 24 months. Although this is only the third sample 
reporting this kind of improvement it is possible that this may be the natural course over at 
least the first two years. Addington et al (2011) in the NAPLS 1 sample, also considered 
social functioning, and suggested that approximately one third may develop a psychotic 
illness, one third may improve and one third may continue to have fluctuating attenuated 
psychotic symptoms and poorer functioning. At this stage it is unclear as to the impact of 
treatments on such division of CHR samples, although the NAPLS 2 project will in the near 
future be able to address many questions related to the impact of treatment on the outcome 
of CHR individuals.
We were also interested in when these early symptoms began. As other SOPS symptoms are 
very difficult to date we focused only on the five positive symptoms. The average age of the 
CHR sample was 18.6 years and they reported that they were on average 16 years old when 
they were aware of the first attenuated psychotic symptom, suggesting an average of >2 
years between first experiencing attenuated psychotic symptoms and seeking help. However, 
this gap actually ranged from 16 days to 19 years. Thus, for some, at their baseline 
assessment these attenuated psychotic symptoms are a new occurrence but for others they 
have been present for much of their lives. The implication is that these individuals who have 
had attenuated psychotic symptoms for many years, often since they were very young, are 
not presenting until either the symptoms worsen, or they begin to impact their functioning or 
they have a new attenuated psychotic symptom appearing. There is, therefore, the possibility 
that some of these CHR individuals could be identified even sooner. This may be 
particularly important for CHR with a long duration of symptoms as this has been shown to 
be one predictor of transition to psychosis in the PACE high risk sample (Nelson et al., 
2013).
In studies of CHR, the outcome that receives the most attention is whether individuals make 
the transition to psychosis. However, in NAPLS 2 we have considered whether individuals 
are in remission from the attenuated psychotic symptoms or continue to present with 
attenuated psychotic symptoms albeit at the same or reduced severity as baseline. We also 
considered those who continue to meet criteria for at least one of the three prodromal 
syndromes. Since the COPS criteria require a worsening, this group is likely to have 
experienced an increase in symptoms over time, although not to the extent that they are of 
psychotic intensity or may have had a remission and then a re-occurrence of symptoms. To 
make the most of our data we examined outcome for those who had completed two years of 
follow-up but also examined outcome using the last outcome rating conducted. What was 
interesting was that although the majority of the baseline prodromal symptoms were 
unrelated to later outcome some symptoms differentiated the transition group from the other 
three groups, e.g., unusual thought content, disorganized communication and overall ratings 
on the disorganized symptoms whereas other symptoms differentiated those in remission 
from the other three groups, e.g., suspiciousness and total positive symptoms. This suggests 
that the presence of certain symptoms may be typical of at risk groups regardless of whether 
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they continue to have symptoms or even make the transition to psychosis; whereas others 
may be predictive of a later psychosis. Interestingly perceptual abnormalities, which was 
one of the most frequently endorsed symptoms at baseline, did not relate at all to later 
outcome.
One limitation of the examination of outcome is that almost 52% of the sample did not 
complete 2 years. Typically it is difficult to keep young people in studies for long periods of 
time, particularly in a study such as NAPLS 2 where in addition to clinical assessments 
participants were also involved in assessments for biological markers; i.e. imaging, EEG, 
blood draws and neurocognition. Dropping out was at times a functioning of individuals 
moving away or changing schools and sites being unable to recontact people. Since most of 
the young people are help-seeking and troubled by the onset of attenuated psychotic 
symptoms, it is not unusual for them to no longer be interested in help once their symptoms 
disappear.
In summary, our results suggest that APSS is by far the most common syndrome among 
those meeting CHR COPS criteria. Positive followed by negative symptoms are the most 
common, in particular, unusual thought content, perceptual abnormalities and 
suspiciousness. However on average all prodromal symptoms rated on the SOPS improve 
over time. For outcome groups based on clinical follow-up there are essentially three 
groups: those who make the transition to psychosis, those who have a remission of 
attenuated psychotic symptoms and those who continue to have attenuated psychotic 
symptoms, some of whom also continue to meet prodromal criteria. Further work with this 
large NAPLS sample will examine both clinical and biological predictors of psychosis. The 
importance of these attenuated positive symptoms will be considered in prediction models. 
However, these results suggest that more in depth study not just of those who convert but 
also of those who present with attenuated psychotic symptoms and who have a complete 
remission of these symptoms often within six months and of those who continue to 
experience at time fluctuating subthreshold symptoms who may not go on to develop a 
psychotic illness, is required. A greater understanding of those who remit may help our 
understanding of psychosis and improve our identification of those who are at real risk of 
developing a psychotic illness. For those who continue to experience attenuated psychotic 
symptoms, further attention to interventions that may help such individuals have improved 
quality of life would be the next step.
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Table 1
Differences in Demographic Characteristics between Clinical High Risk and Healthy Control Participants
Variable Controls n = 280 Prodromal n = 764 Test Statistic Effect Size
Mean (SD) t d
Age in years 19.65 (4.67) 18.45 (4.23) 3.74** 0.26
Years of education 12.68 (3.58) 11.28 (2.82) 5.90** 0.41
Number (%) X2 Cramer's V
Sex
Male 141 (50.4%) 436 (57.1%) 3.73 0.06
Female 139 (49.6%) 328 (42.9%)
Race
First Nations 4 (1.4%) 13 (1.7%) 5.24 0.07
Asian 30 (10.7%) 54 (7.1%)
Black 49 (17.5%) 118 (15.5%)
Latin America/Middle East/White 167 (59.6%) 478 (62.6%)
Native Hawaiian or Pacific Islander 1 (0.4%) 3 (0.4%)
Interracial 29 (10.4%) 97 (12.7%)
Hispanic or Latino
Yes 50 (17.9%) 142 (18.6%) 0.08 0.01
No 230 (82.1%) 621 (81.4%)
Father's highest level of formal education
No or primary school 10.13* 0.10
Some high school 7 (2.6%) 35 (4.9%)
High school and/or some college 13 (4.8%) 72 (10.0%)
College graduate 117 (42.9%) 280 (38.9%)
136 (49.8%) 333 (46.2%)
Mother's highest level of formal education
No or primary school 17.13** 0.13
Some high school 4 (1.4%) 32 (4.3%)
High school and/or some college 8 (2.9%) 59 (7.9%)
College graduate 99 (35.6%) 283 (38.1%)
167 (60.1%) 370 (49.7%)
Marital Status
Single never married 266 (95.0%) 720 (94.9%) 0.01 0.003
Other 14 (5.0%) 39 (5.1%)
Current living arrangement
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Variable Controls n = 280 Prodromal n = 764 Test Statistic Effect Size
Mean (SD) t d
Living with family 177 (63.2%) 576 (75.9%) 25.06** 0.16
Living with spouse/partner 18 (6.4%) 38 (5.0%)
Living on own in apartment/house 31 (11.1%) 40 (5.3%)
Living in group/rooming home 4 (1.4%) 20 (2.6%)
Living with others, not spouse/partner 41 (14.6%) 68 (9.0%)
Living in a shelter 0 (0.0%) 2 (0.3%)
Living on the street 0 (0.0%) 0 (0.0%)
Other 9 (3.2%) 15 (2.0%)
Currently working
Yes 129 (46.1%) 189 (25.0%) 42.65** 0.20
No 151 (53.9%) 567 (75.0%)
Highest level of formal education obtained
High school incomplete 78.81** 0.27
High school graduate 101 (36.1%) 399 (52.7%)
High school and above 92 (32.9%) 289 (38.2%)
87 (31.1%) 69 (9.1%)
Currently enrolled as a student
Yes 227 (81.1%) 624 (82.3%) 0.22 0.01
No 53 (18.9%) 134 (17.7%)
*** p<0.001
*p<0.05
**p<0.01
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Table 2
Frequency and Proportion of Prodromal Syndromes within the Clinical High Risk Sample.
Prodromal Criteria Number %
Attenuated Psychotic Symptom Syndrome (APSS) 641 83.9
Genetic Risk and Deterioration (GRD) 34 4.4
Brief Intermittent Psychotic Symptoms (BIPS) 6 0.8
Under 19 plus Schizotypal Personality Disorder 21 2.7
APSS plus GRD 48 6.3
BIPS plus APSS 12 1.6
BIPS plus APSS plus GRD 2 0.3
Total 764 100%
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Table 3
Frequency at Baseline of the Number of Clinical High Risk Participants Endorsing Each of the 19 Symptoms 
on the Scale of Prodromal Symptoms (N=744)
Symptom Mean (SD) Number (percent) endorsing this symptom >2
Positive Symptoms
Unusual thought content/delusional ideas 3.34 (1.33) 609 (79.6)
Suspiciousness/persecutory ideas 2.76 (1.51) 498 (65.1)
Grandiosity 1.00 (1.30) 121 (15.8)
Perceptual abnormalities/hallucinations 3.07 (1.50) 568 (74.2)
Disorganized communication 1.75 (1.47) 227 (29.7)
Negative Symptoms
Social anhedonia 2.36 (1.74) 314 (42.3)
Avolition 2.45 (1.62) 384 (52.4)
Expression of emotion 1.36 (1.52) 188 (25.7)
Experience of emotions and self 1.75 (1.68) 283 (38.7)
Ideational richness 1.16 (1.31) 142 (19.4)
Occupational functioning 2.84 (2.01) 414 (56.4)
Disorganization Symptoms
Odd behavior or appearance 0.84 (1.20) 94 (12.8)
Bizarre thinking 0.91 (1.20) 91 (12.4)
Trouble with focus and attention 2.64 (1.28) 434 (59.2)
Impairment in personal hygiene 0.76 (1.21) 77 (10.5)
General Symptoms
Sleep disturbance 2.32 (1.56) 384 (52.3)
Dysphoric mood 3.34 (1.61) 507 (67.9)
Motor disturbances 0.83 (1.06) 45 (6.1)
Impaired tolerance to normal stress 2.70 (1.88) 381 (52.0)
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Table 4
Clinical Outcome of Clinical High Risk Participants at End of Study
IN REMISSION SYMPTOMATIC PRODROMAL PROGRESSION PSYCHOTIC
n (%) n (%) n (%) n (%)
2 YEARS 109/367a (29.7%) 93/367 (25.3%) 72/367 (19.6%) 93/367 (25.3%)
LOCF 171/613b (27.9%) 186/613 (30.3%) 163/613 (26.6%) 93/613 (15.2%)
LOCF - Last assessment carried forward
a367 is the number of converters plus the CHR participants who completed a 2 year followup
b613 is the number of converters plus the CHR participants who completed at least one followup
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Table 5
Post Hoc Analyses of the Baseline Differences between the Clinical Outcome Groups
BASELINE SOPS SYMPTOM LOCF CLINICAL OUTCOME 24 MONTH CLINICAL OUTCOME
P1 - Unusual thought content Psychotic > Remission***
Psychotic > Symptomatic**
Psychotic >Prodromal Progression*
Prodromal Progression > Remission*
Prodromal Progression > Symptomatic*
Psychotic > Remission***
Psychotic > Symptomatic**
Prodromal Progression > Remission**
P2 - Suspiciousness Remission < Symptomatic***
Remission < Prodromal Progression**
Remission < Psychotic***
Remission < Symptomatic**
Remission < Psychotic***
P5 - Disorganization Psychotic > Remission***
Psychotic >Symptomatic*
Psychotic >Prodromal Progression***
Psychotic > Remission**
Psychotic >Prodromal Progression**
N2 - Avolition Remitted < Symptomatic* NS
Positive total Remission < Symptomatic***
Remission < Prodromal Progression*
Remission < Psychotic***
Symptomatic < Psychotic*
Prodromal Progression < Psychotic**
Remission < Symptomatic**
Remission < Prodromal Progression*
Remission < Psychotic***
Disorganization total Psychotic > Remission***
Psychotic > Prodromal Progression**
Psychotic > Symptomatic*
Psychotic > Remission***
LOCF=Last observation carried forward
*p<0.05
**p<0.01
***p<0.001
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